144 related articles for article (PubMed ID: 34894455)
1. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Plummer R; Dean E; Arkenau HT; Redfern C; Spira AI; Melear JM; Chung KY; Ferrer-Playan J; Goddemeier T; Locatelli G; Dong J; Fleuranceau-Morel P; Diaz-Padilla I; Shapiro GI
Lung Cancer; 2022 Jan; 163():19-26. PubMed ID: 34894455
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Middleton MR; Dean E; Evans TRJ; Shapiro GI; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R
Br J Cancer; 2021 Aug; 125(4):510-519. PubMed ID: 34040175
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI; Wesolowski R; Devoe C; Lord S; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R; Yap TA
Br J Cancer; 2021 Aug; 125(4):520-527. PubMed ID: 34040174
[TBL] [Abstract][Full Text] [Related]
4. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Pal SK; Frankel PH; Mortazavi A; Milowsky M; Vaishampayan U; Parikh M; Lyou Y; Weng P; Parikh R; Teply B; Dreicer R; Emamekhoo H; Michaelson D; Hoimes C; Zhang T; Srinivas S; Kim WY; Cui Y; Newman E; Lara PN
JAMA Oncol; 2021 Oct; 7(10):1536-1543. PubMed ID: 34436521
[TBL] [Abstract][Full Text] [Related]
5. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Terranova N; Jansen M; Falk M; Hendriks BS
Cancer Chemother Pharmacol; 2021 Feb; 87(2):185-196. PubMed ID: 33145616
[TBL] [Abstract][Full Text] [Related]
7. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR; Lord S; El Badri S; Harman R; Holmes J; Kamzi F; Maughan T; McIntosh D; Mukherjee S; Ooms A; Radhakrishna G; Shaw P; Hawkins MA
Br J Cancer; 2024 Feb; 130(3):467-475. PubMed ID: 38129525
[TBL] [Abstract][Full Text] [Related]
8. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
Mylonakis N; Athanasiou A; Ziras N; Angel J; Rapti A; Lampaki S; Politis N; Karanikas C; Kosmas C
Lung Cancer; 2010 May; 68(2):240-7. PubMed ID: 19628292
[TBL] [Abstract][Full Text] [Related]
13. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Baek JH; Kim H; Ahn JJ; Jegal Y; Seo KW; Ra SW; Park CR; Jung JP; Kim JW; Lee YJ; Cha HJ; Kwon WJ; Noh YJ; Oh S; Park JH; Min YJ
Lung Cancer; 2012 Jun; 76(3):368-72. PubMed ID: 22192919
[TBL] [Abstract][Full Text] [Related]
15. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
16. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
Br J Cancer; 2017 Sep; 117(7):938-946. PubMed ID: 28950288
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]